Azurin, Plasmodium falciparum malaria and HIV/AIDS: Inhibition of parasitic and viral growth by azurin

Cell Cycle

Volumn 5, Issue 15, 2006, Pages 1642-1648

  Chaudhari, Anita ^a   Fialho, Arsenio M ^a,e   Ratner, Deena ^c   Gupta, Phalguni ^c   Hong, Chang Soo ^a   Kahali, Soumen ^a   Yamada, Tohru ^a   Haldar, Kasturi ^b   Murphy, Sean ^b   Cho, Wonhwa ^a   Chauhan, Virander S ^d   Das Gupta, Tapas K ^a   Chakrabarty, Ananda M ^a,f  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^e INSTITUTO SUPERIOR TÉCNICO   (Portugal)

^f UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Azurin; CD4; H.8 epitope; HIV 1 entry; HIV 1 envelope glycoprotein gp120; Merozoite surface protein 1; Parasitemia

Indexed keywords

AZURIN; EPITOPE; GLYCOPROTEIN GP 120; H 8 AZURIN; IMMUNOGLOBULIN; INTERCELLULAR ADHESION MOLECULE 3; MEROZOITE SURFACE PROTEIN 1; PROTEIN; PROTEIN LAZ; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AMINO TERMINAL SEQUENCE; ANTIMALARIAL ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; ELECTRON TRANSPORT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALARIA; NEISSERIA GONORRHOEAE; NEISSERIA MENINGITIDIS; NONHUMAN; PARASITEMIA; PLASMODIUM FALCIPARUM; PROTEIN BINDING; PROTEIN DOMAIN; VIROGENESIS;

HUMAN IMMUNODEFICIENCY VIRUS 1; PLASMODIUM FALCIPARUM;

EID: 33747854509     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.5.15.2992     Document Type: Article

References (41)

1. World Health Organization. Report No.: WHO/HIV/2004.08. Geneva, Switzerland: 2004.
2. Fauci AS, Touchette NA, Folkers GK. Emerging infectious diseases: A 10-year perspective from the National Institute of Allergy and Infectious Diseases. Emerg Infec Dis 2005; 11:519-25.
3. Chandramohan D, Greenwood BM. Is there an interaction between human immunodeficiency virus and Plasmodium falciparum? Int J Epidemiol 1998; 27:296-301.
4. Korenromp EL, Williams BG, de Vlas SJ, Gouws E, Gilks CF, Ghys PD, Nahlen BL. Malaria attributable to the HIV-1 epidemic, sub-Saharan Africa. Emerg Inf Dis 2005; 11:1410-9.
5. Fauci AS. HIV and AIDS: 20 years of science. Nature Med 2003; 9:839-43.
6. Kamya MR, Kigonya CN, McFarland W. HIV infection may adversely affect clinical response to chloroquine therapy for uncomplicated malaria in children. AIDS 2001; 15:1187-8.
7. Yamada T, Fialho AM, Punj V, Bratescu L, Das Gupta TK, Chakrabarty AM. Internalization of bacterial redox protein azurin in mammalian cells: Entry domain and specificity. Cell Microbiol 2005; 7:1418-31.
8. Yamada T, Goto M, Punj V, Zaborina O, Chen ML, Kimbara K, Majumdar D, Cunningham E, Das Gupta TK, Chakrabarty AM. Bacterial redox protein azurin, tumor suppressor protein p53, and regression of cancer. Proc Natl Acad Sci USA 2002; 99:14098-103.
9. Punj V, Bhattacharyya S, Saint-Dic D, Vasu C, Cunningham EA, Graves J, Yamada T, Constantinou AI, Christov K, White B, Li G, Majumdar D, Chakrabarty AM, Das Gupta TK. Bacterial cupredoxin azurin as an inducer of apoptosis and regression in human breast cancer. Oncogene 2004; 23:2367-78.
10. Liao Z, Roos JW, Hildreth JEK. Increased infectivity of HIV type 1 particles bound to cell surface and solid-phase ICAM-1 and VCAM-1 through acquired adhesion molecules LFA-1 and VLA-4. AIDS Res Hum Retroviruses 2000; 16:355-66.
11. Hioe CE, chien PC, Lu C, Springer TA, Wang XH, Bandres J, Tuen M. LFA-1 expression on target cells promotes human immunodeficiency virus type 1 infection and transmission. J Virol 2001; 75:1077-82.
12. Wassmer SC, Cianciolo GJ, Combes V, Grau GE. Inhibition of endothelial activation: A new way to treat cerebral malaria? PloS Med 2005; 2:885-90.
13. Dormeyer M, Adams Y, Kramer B, Chakravorty S, Tse MT, Pegoraro S, Whittaker L, Lanzer M, Craig A. Rational design of anticytoadherence inhibitors for Plasmodium falciparum based on the crystal structure of human intercellular adhesion molecule 1. Antimicrob Agents Chemotherap 2006; 50:724-30.
14. Hong CS, Yamada T, Fialho AM, Das Gupta TK, Chakrabarty AM. Disrupting the entry barrier and attacking brain tumors: The role of the Neisseria H.8 epitope and the Laz protein. Cell Cycle 2006; In press.
15. Gough J, Chothia C. The linked conservation of structure and function in a family of high diversity: The monomeric cupredoxins. Structure 2004; 12:917-25.
16. Stevens FJ, Kuemmel C, Babnigg G, Collart FR. Efficient recognition of protein fold at low sequence identity by conservative application of Psi-BLAST: Application. J Mol Recognit 2005; 18:150-7.
17. Holm L, Park J. DaliLite workbench for protein structure comparison. Bioinformatics 2000; 16:566-7.
18. Michalopoulos I, Torrance GM, Gilbert DR, Westhead DR. TOPS: An enhanced database of protein structural topology. Nucleic Acid Res 2004; 32:D251-4.
19. Pizarro JC, Chitarra V, Verger D, Holm I, Petres S, Dartevelle S, Nato F, Longacre S, Bentley GA. Crystal structure of a Fab complex formed with Pf MSP1-19, the C-terminal fragment of merozoite surface protein 1 from Plasmodium falciparum: A malaria vaccine candidate. J Mol Biol 2003; 328:1091-103.
20. Ryu SE, Truneh A, Sweet RW, Hendrickson WA. Structures of an HIV and MHC binding fragment from human CD4 as refined in two crystal lattices. Structure 1994; 2:59-74.
21. Song G, Yang Y, Liu JH, Casasnovas JM, Shimaoka M, Springer TA, Wang JH. An atomic resolution view of ICAM recognition in a complex between the binding domains of ICAM-3 and integrin alphaLbeta2. Proc Natl Acad Sci USA 2005; 102:3366-71.
22. Wilson CJ, Wittung-Stafshede P. Role of structural determinants in folding of the sandwich-like protein Pseudomonas aeruginosa azurin. Proc Natl Acad Sci USA 2005; 102:3984-7.
23. Cowman AF, Baldi DL, Healer J, Mills KE, O'Donnell RA, Reed MB, Triglia T, Wickham ME, Crabb BS. Functional analysis of proteins involved in Plasmodium falciparum merozoite invasion of red blood cells. FEBS Lett 2000; 476:84-8.
24. Baum J, Richard D, Healer J, Rug M, Krnajski Z, Gilberger TW, Green JL, Holder AA, Cowman AF. A conserved molecular motor drives cell invasion and gliding motility across malaria life cycle stages and other apicomplexan parasites. J Biol Chem 2006; 281:5197-208.
25. Blackman MJ, Scott-Finnigan TJ, Shai S, Holder AA. Antibodies inhibit the protease-mediated processing of a malaria merozoite surface protein. J Exp Med 1994; 180:389-93.
26. Egan AF, Morris J, Barnish G, Allen S, Greenwood BM, Kaslow DC, Holder AA, Riley EM. Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, Pf MSP-1. J Infect Dis 1996; 173:765-69.
27. Nwuba RI, Sodeinde O, Anumuda CI, Omusun YO, Odaibo AB, Holder AA, Ngagwu M. The human immune response to Plasmodium falciparum includes both antibodies that inhibit merozoite surface protein 1 secondary processing and blocking antibodies. Infect Immun 2002; 70:5328-31.
28. Gotschlich EC, Blake MS, Koomey JM, Seiff M, Derman A. Cloning of the structural genes of three H8 antigens and of protein III of Neisseria gonorrhoeae. J Exp Med 1986; 43:868-81.
29. Kawula TH, Spinola SM, Klapper DG, Cannon JG. Localization of a conserved epitope and an azurin-like domain in the H.8 protein of pathogenic Neisseria. Mol Microbiol 1987; 1:179-85.
30. Smith JD, Craig AG, Kriek N, Hudson-Taylor D, Kyes S, Fagen T, Pinches R, Baruch, DI, Newbold CI, Miller LH. Identification of a Plasmodium falciparum intercellular adhesion molecule-1 binding domain: A parasite adhesion trait implicated in cerebral malaria. Proc Natl Acad Sci USA 2000; 97:1766-71.
31. Franke-Fayard B, Janse CJ, Cunha-Rodrigues M, Ramesar J, Buscher P, Que I, Lowik C, Voshol PJ, den Boer MAM, van Duinen SG, Febbraio M, Mota MM, Waters AP. Murine malaria parasite sequestration: CD36 is the major receptor, but cerebral pathology is unlinked to sequestration. Proc Natl Acad Sci USA 2005; 102:11468-73.
32. Geijtenbeek TB, Torensma R, van Vliet SJ, van Duijnhoven GC, Adema GJ, van Kooyk Y, Figdor CG. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 2000; 100:575-85.
33. Soilleux EJ. DC-SIGN (dendritic cell-specific ICAM-grabbing nonintegrin) and DC-SIGN-related (DC-SIGNR): Friend or foe? Clin Sci 2003; 104:437-46.
34. Geijtenbeek TB, van Vliet SJ, van Duijnhoven GC, Figdor CG, van Kooyk Y. DC-SIGN, a dentritic cell-specific HIV-1 receptor present in placenta that infects T cells in trans - A review. Placenta 2001; 22:S 19-23.
35. Snyder GA, Ford J, Torabi-Parizi P, Arthos JA, Schuck P, Colonna M, Sun PD. Characterization of DC-SIGN/R interaction with human immunodeficiency virus type 1 gp120 and ICAM molecules favors the receptor's role as an antigen-capturing rather than an adhesion receptor. J Virol 2005; 79:4589-98.
36. Barat C, Gervais P, Tremblay MJ. Engagement of ICAM-3 provides a costimulatory signal for human immunodeficiency virus type 1 replication in both activated and quiescent CD4+ T lymphocytes: Implications for virus pathogenesis. J Virol 2004; 78:6692-7.
37. Katsnelson A. Biotech jostles with pharma for slice of HIV market. Nature Biotechnol 2006; 24:3-4.
38. Rao S, Hu S, McHugh L, Lueders K, Henry K, Zhao Q, Fekete RA, Kar S, Adhya S, Hamer DH. Toward a live microbial microbicide for HIV: Commensal bacteria secreting an HIV fusion inhibitor peptide. Proc Natl Acad Sci USA 2005; 102:11993-8.
39. Lagenaur LA, Berger EA. An anti-HIV microbicide comes alive. Proc Natl Acad Sci USA 2005; 102:12294-5.
40. Yamada T, Hiraoka Y, Das Gupta TK, Chakrabarty AM. Regulation of mammalian cell growth and death by bacterial redox proteins: Relevance to ecology and cancer therapy. Cell Cycle 2004; 3:752-5.
41. 1 arrest in J774 and apoptosis in human cancer cells. Cell Cycle 2004; 3:1182-7.